Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors
| Status: | Completed |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/8/2017 |
| Start Date: | November 2000 |
| End Date: | May 2005 |
To determine the safety and efficacy of the combination of Etanercept and Docetaxel in
patients with advanced solid tumors for which there is no standard treatment.
patients with advanced solid tumors for which there is no standard treatment.
Inclusion Criteria:
- Must have pathologically or cytologically confirmed advanced solid malignancy for
which there is no standard treatment exists.
- Solid malignancy that has persisted or recurred following prior therapy or advanced
solid malignancy for which docetaxel is considered an acceptable first line treatment
option:
- Non-Small Cell Lung
- Breast
- Head and Neck
- Esophageal
- Stomach
- Ovarian carcinomas
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
- Life expectancy of at least 12 weeks.
- Must have adequate organ function
- Peripheral Neuropathy must be less than Grade 2
We found this trial at
1
site
Click here to add this to my saved trials
